LAS VEGAS, May 23, 2017, GBLX, /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (“MCCM”). The current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free ofRead more
- Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
- PHI Group Partners with Fintech Green Investment Company
- Third and Fourth Quarters 2018 Expected to See Continued Advancements for the Pura Natural’s Grease Beast Products Amid Approval as an Available Vendor to All True Value and Ace Hardware Stores
- Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.
- Wrap Technologies Secures First Patent – Recaps IP Strategy
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More